Pharmafile Logo
Pharmafocus logo
Advanced Search

Product roundup from Datamonitor

June 4, 2007
Sales and Marketing

Celsion completes enrolment in phase I liver cancer studyCelsion has completed its phase I dose escalation study, using ThermoDox, to …

News

Clew to promote Novartis’ Aclasta

May 31, 2007
Medical Communications

Novartis has appointed Clew Communications to run a pre-launch and launch PR campaign for its new osteoporosis drug.Aclasta (zoledronic acid) …

News

NICE approves Pfizer’s Champix

May 31, 2007

Pfizer's first-in-class smoking cessation drug Champix has received approval from NICE one month before England's smoking ban comes into effect.Champix …

News

China’s former medicines regulator sentenced to death

May 31, 2007
Sales and Marketing

The former head of China's medicines regulator has been sentenced to death after being found guilty of taking bribes to …

News

Genzyme buys cancer specialists Bioenvision

May 31, 2007
Research and Development

Genzyme is to spend $345 million on acquiring specialist pharma company Bioenvision and its oncology portfolio.Genzyme already co-markets with Bioenvision …

News

Avandia safety concerns hit GSK shares

May 31, 2007
Sales and Marketing

Shares in GSK have taken another hit after news that US prescribers have turned away from diabetes drug Avandia in …

News

Product roundup from Datamonitor

May 29, 2007
Sales and Marketing

ADHD drug as effective in boys as girls, says ShireUK pharmaceutical company Shire has said that results from a study …

News

Industry outlines concerns with NICE to Parliament

May 24, 2007

NICE's shortfalls have compromised public confidence in the cost and clinical-effectiveness body, the pharmaceutical industry has told MPs.The comments were …

News

PCTs ‘overspending’ on prescribing

May 24, 2007

PCTs could save the NHS more than £200 million if they can persuade more GPs to prescribe generically, according to …

News

Report raises safety concerns over Avandia

May 24, 2007
Sales and Marketing

GlaxoSmithKline has been forced on the defensive after its blockbuster diabetes treatment Avandia was linked to an increased risk of …

News

The Changing Face of Medical Education

May 23, 2007
Medical Communications, Sales and Marketing medical education

Is Medical Education the new PR?Phil Sheldon, Managing Director, Resolute Communications:Clients are increasingly waking up to the fact that medical …

Feature

Charity outlines vision for tackling cancer

May 23, 2007
Sales and Marketing

Cancer Research UK has set out an ambitious list of goals to reach by 2020, which it hopes will inspire …

News

Pfizer loses heads of research and finance

May 23, 2007
Research and Development, Sales and Marketing

Two key Pfizer executives are to step down as the company continues its drive to reinvigorate itself.The departures follow the …

News

Edelman scoops European Viagra account

May 23, 2007
Medical Communications

Pfizer has appointed PR agency Edelman to raise the European profile of its blockbuster erectile dysfunction treatment, Viagra.The company has …

News

Latest news from Datamonitor

May 23, 2007
Sales and Marketing

Breast cancer patients may be offered chemo-free treatmentHormone therapy drugs such as AstraZeneca's Zoladex may be as effective as traditional …

News

Med Ed comes of age

May 17, 2007
Medical Communications, Sales and Marketing medical education

Even a casual observer will have noticed the large contribution pharma makes to postgraduate medical education, both in the UK …

Feature

Roche selects Ketchum for pandemic work

May 17, 2007
Medical Communications

PR agency Ketchum has scooped a global account for Tamiflu as Roche begins further research into its use against bird …

News

Clinical news from Datamonitor

May 17, 2007
Research and Development

FDA requests additional efficacy data for Dendreon's Provenge in advanced prostate cancer.Dendreon has received a complete response letter from the …

News

Pharma news from Datamonitor

May 17, 2007
Sales and Marketing

Meda and Ethypharm collaborate on NSAIDMeda and Ethypharm have signed an exclusive 15-year agreement for an innovative NSAID product which …

News

NICE blocks Erbitux for head and neck cancer

May 17, 2007

Merck's targeted cancer drug Erbitux has been rejected by NICE for use against head and neck cancer.The Watchdog's Final Appraisal …

News
The Gateway to Local Adoption Series

Latest content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Sandoz’ Ondibta receives European Commission approval for diabetes

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026